Clinical Trials Logo

Filter by:
NCT ID: NCT03890744 Completed - Clinical trials for Metastatic Breast Cancer

ModraDoc006/r in Patients With Breast Cancer

Start date: January 30, 2019
Phase: Phase 2
Study type: Interventional

This is a multicenter phase IIa study to evaluate the efficacy and tolerability of ModraDoc006 in combination with ritonavir (denoted ModraDoc006/r) in patients with recurrent or metastatic HER-2 negative breast cancer, that are suitable for treatment with a taxane as 1st-3rd line of therapy.

NCT ID: NCT03890367 Completed - Clinical trials for Meningococcal Immunisation (Healthy Volunteers)

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers

Start date: September 12, 2019
Phase: Phase 3
Study type: Interventional

Primary Objective: To demonstrate: - the non-inferiority of the seroprotection rate (antibody titers greater than or equal to [>=] 1:8) to meningococcal serogroup C following the administration of MenACYW Conjugate or Nimenrix® as measured by serum bactericidal assay using human complement (hSBA). If this non-inferiority was demonstrated, then - the non-inferiority of the antibody response (geometric mean titers [GMT]). If this non-inferiority was demonstrated, then - the superiority of the antibody response (GMT). If this superiority was demonstrated, then - the superiority of the seroprotection rate. Or to demonstrate: - the non-inferiority of the seroprotection rate (antibody titers >= 1:8) to meningococcal serogroup C following the administration of MenACYW Conjugate or NeisVac-C® as measured by serum bactericidal assay using baby rabbit complement (rSBA). If this non-inferiority was demonstrated, then - the non-inferiority of the antibody response (GMT). If this non-inferiority was demonstrated, then - the superiority of the antibody response (GMT). Secondary Objective: To demonstrate: - the non-inferiority of the seroprotection rate (antibody titers >= 1:8) to meningococcal serogroup C following the administration of MenACYW Conjugate vaccine or Nimenrix® as measured by rSBA. If this non-inferiority was demonstrated, then - the non-inferiority of the antibody response (GMT). If this non-inferiority was demonstrated, then - the superiority of the antibody response (GMT). Or to demonstrate: - the non-inferiority of the seroprotection rate (antibody titers >= 1:8) to meningococcal serogroup C following the administration of MenACYW Conjugate vaccine or NeisVac-C® as measured by hSBA. If this non-inferiority was demonstrated, then - the non-inferiority of the antibody response (GMT). If this non-inferiority was demonstrated, then - the superiority of the antibody response (GMT) .

NCT ID: NCT03889184 Completed - Rehabilitation Clinical Trials

An Innovative Rehabilitating Meals-on-wheels Service for Frail Old People

Start date: March 18, 2019
Phase: N/A
Study type: Interventional

The aim of the project is to assess the beneficial effect of offering frail old people a targeted meals-on-wheels service in 8 weeks in a randomized controlled trial

NCT ID: NCT03887520 Completed - Clinical trials for Cardiovascular Disease and Lipoprotein(a)

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

Start date: November 27, 2018
Phase: N/A
Study type: Interventional

The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).

NCT ID: NCT03887325 Completed - Headache, Migraine Clinical Trials

The Effects of Maxipost (BMS 204352) on Cerebral Hemodynamic and Headache in Healthy Volunteers and Migraine Patients

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

It is not previously investigated whether, there is a correlation between potassium channels and migraine, so it is unclear whether, this signaling pathway through potassium channels has an impact on migraine pathophysiology. Maxipost (BMS 204352) is a vasoactive molecule that causes vasodilation via the big calcium dependent potassium (BKCa) channel signaling pathway. Maxipost decreases the blood pressure and maxipost infusion causes headache in healthy volunteers. A possible coherence between maxipost and headache/migraine in healthy volunteers and migraine patients is yet to be investigated. The present study aims to clarify a possible coherence between maxipost and headache/migraine and it will help to shed light on the importance of potassium channels in migraine. In general, the study will contribute to a greater understanding of migraine pathogenesis and possibly lead to development of specific migraine treatment.

NCT ID: NCT03886883 Completed - Pain Threshold Clinical Trials

Endogenous Modulation of Pain and Stretch Tolerance

Start date: October 1, 2017
Phase: N/A
Study type: Interventional

This study investigates the role of two endogenous inhibitory mechanisms; exercise-induced hypoalgesia (EIH) and a conditioning painful stimulus (CPM) on passive joint range of motion, passive resistive torque and pain sensitivity. The study is a randomized, repeated-measures cross-over study.

NCT ID: NCT03886259 Completed - Chronic Pain Clinical Trials

Effects of Exercise and Education in Patients With Chronic Pain After Total Knee Replacement

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate whether a 12-week neuromuscular rehabilitation program (NEMEX-TJR) combined with pain neuroscience education (PNE) provides greater pain relief, improvement in physical function and quality of life than PNE alone in a population of patients with chronic pain after primary total knee arthroplasty. Hypothesis: Rehabilitation involving neuromuscular training and PNE will provide greater pain relief, improved function and improved quality of life compared to PNE alone at the primary endpoint, which is follow-up 12months after the start of the treatment.

NCT ID: NCT03881644 Completed - Clinical trials for Migraine Without Aura

PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine

Start date: July 17, 2018
Phase: N/A
Study type: Interventional

The aim is to investigate the incidence of headache, migraine attacks and flushing after pituitary adenylate cyclase-activating peptide-38 (PACAP38) with and without treatment with sumatriptan in patients with migraine

NCT ID: NCT03880994 Completed - Clinical trials for Cognitive Impairment

Mental Health of Men Before and After Testicular Cancer Treatment

Start date: March 25, 2019
Phase:
Study type: Observational [Patient Registry]

This is a prospective observational study, that investigates men diagnosed with testicular cancer before and after treatment. The patients are included at their visit at the Fertility clinic in Horsens, where they deposit semen for cryopreservation prior to surgery and potential systemic treatment. Here the patients, who want to participate will perform a cognitive test and afterwards complete a questioner (T1). After 9 month the patients will be invited to perform the cognitive test and complete the questionnaire again (T2).

NCT ID: NCT03878940 Completed - Cancer Clinical Trials

A Feasibility Study of Direct Access to an Abdominal ´Yes-No´ Pathway for Primary Care Patients

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

Background To optimise cancer outcome in Denmark, cancer diagnostic pathways should, beside cancer patient pathways (CPP) for alarm symptoms, also include a pathway for patients with vague and non-specific symptoms. Research has demonstrated that 50% of all cancers do not qualify for specific CPPs, although the majority of patients initially present symptoms in general practice. Hypothesis Direct access to an abdominal `yes-no' pathway is feasible in general practice. Aim The aim of this study is to assess the implementation and clinical implications of direct access to an abdominal `yes-no' pathway for primary care patients with vague and non-specific abdominal symptoms Materials and methods The study is a feasibility study in which all general practitioners (GPs) in the municipality of Silkeborg in Central Denmark Region are offered direct access to a newly developed abdominal ´yes-no´ pathway for both men and women aged 30 years or above, who present vague and non-specific abdominal symptoms in primary care. The abdominal ´yes-no´ pathway consists of: 1) Medical and objective examination, 2) Selected blood samples and a Fecal Immunochemical test (FIT), and 3) Abdominal ultrasound (US) and transvaginal US (TVUS) (for women). Perspectives This study will provide important knowledge on how to improve abdominal cancer diagnostics in general practice.